retatrutide phase 2 type 2 diabetes trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide, a TRIPLE agonist (GLP1,
Description
Breaking a weight-loss plateau on GLP-1
The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S
Heath Secretary Robert F
Materials and Methods This was a single centre retrospective observational study conducted at a Swiss bariatric reference centre
FDA is acknowledging that the drugs dont have the same risk seen with older weight-loss medicines
